Frailty was a significant predictor of severe outcomes and hospitalization characteristics in older adults hospitalized with RSV infection.

“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

Arexvy is currently approved to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older, and those 50 to 59 years of age who are at increased risk for LRTD ...

Each year, almost 200,000 adults 65 and older are hospitalized due to RSV, and an estimated 14,000 of those cases result in ...

Shifts in RSV testing methodology, which were accelerated by changes related to the COVID-19 pandemic, mirror shifts seen in ...

Researchers at MIT and other institutions have identified compounds that can fight off viral infection by activating a ...

MIT researchers identified compounds that can fight off viral infection by activating a defense pathway inside host cells. These compounds could be used as antiviral drugs that work against not just ...

The rapid identification of respiratory virus outbreaks is needed to enable rational and effective public health interventions. We developed new quantitative approaches for simultaneous ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially deadly RSV.

The human body is naturally equipped with defenses to fight off viral infections. For a virus to successfully infect it, it must first overcome these defenses. To do so, viruses have evolved ...

How preventing RSV, a respiratory virus especially harmful to babies, pays off New prevention measures for RSV have led to a major drop in hospitalizations among infants, according to a new CDC study.

Respiratory Syncytial Virus or RSV is one of the most common respiratory viruses circulating today. Often thought of as only being dangerous to babies and toddlers due to how often child-related ...